Kontrol BioCloud Delivers Multiple Successful Real-Time COVID-19 Detections

Rhea-AI Summary

Kontrol Technologies Corp. (OTCQB:KNRLF) has confirmed the effectiveness of its BioCloud technology in detecting COVID-19 via independent laboratory testing. The technology recorded positive detection results from four individuals, backed by real-time data analytics. CEO Paul Ghezzi noted this as a significant milestone, promising valuable data for partners and researchers. A conference call is scheduled for November 15, 2021, at 4:30 PM EST to discuss Q3 2021 financial results. For detailed analytics, visit BioCloud's report.

Positive

• Confirmed effective COVID-19 detection through BioCloud technology.
• Real-time data analytics provide valuable insights for partners.
• Independent laboratory testing supports positive detection results.

Negative

• None.

-BioCloud Positive Detection Confirmed by Third-Party Laboratory Testing and Generates Significant Data and Analytics-

TORONTO--(BUSINESS WIRE)-- Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) ("Kontrol" or the "Company") a leader in smart buildings and cities through IoT, Cloud and SaaS technology, today announced that the Kontrol BioCloud (or "BioCloud") technology delivered repeated, real-time detections of COVID-19 from four individuals.

The successful detection was completed as part of Kontrol's internal data, analytics, and reporting, as supported by PCR testing and independent laboratory confirmation of positive detection results.

"Completing multiple successful positive detections represents another significant milestone achieved for BioCloud,” said Paul Ghezzi, CEO of Kontrol. “In addition, we were able to collect a significant amount of real-time data that will provide additional value to our partners, customers and other applicable relevant organizations. The in-field validation provides critical information on the operation of BioCloud in the presence of the SARS-CoV-2 virus and further advances BioCloud as a leading ambient air monitoring technology."

The data collocated is based on a number of metrics which are divided into four primary sections in the results compiled by the Company. See link to report at https://kontrolbiocloud.com/positivedetection

• Determination of BioCloud detection response in a defined area
• Determination of SARS-CoV-2 viral collection efficiency from the BioCloud analyzer target system with independent validation from a laboratory PCR test
• Examine and monitor SARS-CoV-2 virus concentration distribution and variations in a defined area during various uses of that area
• Examine participant viral shedding response over a period of time

"BioCloud was designed as an early detection system for viruses and pathogens by continuously monitoring and sampling the ambient air in rooms where individuals gather," said Gary Saunders, President of Kontrol BioCloud. "The results achieved through real-time detection of the SARS-CoV-2 virus is further validation of the value of our technology, and the important data collected in real-time will be shared with researchers and government agencies.”

Further updates on BioCloud will be provided on the Q3 Conference Call.

Kontrol will host a conference call on Monday, November 15th, 2021, at 4:30 PM EST to discuss Kontrol’s third quarter 2021 financial results. To participate, please use the following information:

Title:	Kontrol Technologies Reports Q3 2021 Financial Results
Event Date and Time:	Monday, November 15, 2021, at 4:30 PM EST
Event Duration:	30 Minutes
Event Link:	Kontrol Technologies Q3 2021 Webcast
Conference Call- in Numbers:	Toronto Local: 416-764-8609 North American Toll Free: 888-390-0605
Confirmation #:	51630465

Please dial in at least 5 minutes before the call start time to ensure timely participation.

About Kontrol BioCloud^TM

Kontrol BioCloud (“BioCloud”) is an operating subsidiary of Canadian public company Kontrol Technologies. The BioCloud technology is a real-time analyzer designed to detect airborne viruses and pathogens. BioCloud is an air quality technology and not a medical device. BioCloud has been designed to operate as a safe space technology by sampling the air quality continuously. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and a silent notification system is created. BioCloud can be applied to any space where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

About Kontrol Technologies Corp.

Kontrol Technologies Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Technologies Corp. can be found on its website at www.kontrolcorp.com and by reviewing its profile on SEDAR at www.sedar.com

https://facebook.com/kontroltechcorp/
https://twitter.com/kontrolgroup
https://www.linkedin.com/company/kontrol-group

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may", "will", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions, and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy.

Where Kontrol expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company's product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. Kontrol BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005832/en/

Kontrol Technologies Corp.

Paul Ghezzi

CEO

info@kontrolcorp.com

180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8

Tel: (905) 766.0400

Investor Relations:

Brooks Hamilton

MZ Group – MZ North America

KNRLF@mzgroup.us

Tel: +1 (949) 546.6326

Source: Kontrol Technologies Corp.

FAQ

What is the significance of Kontrol Technologies' BioCloud detection results?

Kontrol Technologies' BioCloud technology has successfully detected COVID-19, confirming its effectiveness and providing valuable data for further analysis.

When is the Q3 conference call for Kontrol Technologies?

The Q3 conference call for Kontrol Technologies is scheduled for November 15, 2021, at 4:30 PM EST.

What data was collected from the BioCloud technology testing?

The testing of BioCloud technology collected data on detection response, viral shedding, and SARS-CoV-2 concentration distribution, validated by PCR testing.

How does BioCloud technology work in detecting airborne viruses?

BioCloud continuously monitors and samples ambient air to detect the presence of airborne viruses and pathogens, ensuring a safe environment.

What stock symbol is associated with Kontrol Technologies?

Kontrol Technologies is traded under the stock symbol OTCQB:KNRLF.